
vTv Therapeutics Inc.: updates and filings
Price
$15.51
November 20, 2026Market cap $62M
What Ploutos Investor adds for vTv Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 13 fiscal years, from 2013
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 29% since Nov 5, 2026, when the 10-Q these figures come from was filed ($21.74 then, $15.51 on Nov 20, 2026). The figures date from before that move.10-Q
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 5, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
March 2026
February 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 5, 2026Results of operationsForm8-K
- Oct 8, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 6, 2026Amended articles or bylawsForm8-K
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operationsForm8-K
- Jul 29, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 29, 2026Shareholder voteForm8-K
- Jun 10, 2026Additional annual meeting materialFormDEFA14A
- May 13, 2026Other material eventsForm8-K
- May 13, 2026Shares registered for employeesFormS-8
- May 13, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 13, 2026Results of operationsForm8-K
- Apr 28, 2026Annual meeting proxy statementFormDEF 14A
- Apr 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 27, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Mar 10, 2026Regulation FD disclosureForm8-K
- Mar 10, 2026Results of operationsForm8-K
- Mar 10, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 26, 2026Regulation FD disclosureForm8-K
- Feb 2, 2026Material agreement enteredForm8-K
- Dec 19, 2025Amended articles or bylawsForm8-K
- Dec 9, 2025Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Nov 24, 2025FilingFormEFFECT
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 5, 2026 | 8-K | Results of operations | Document |
| Oct 8, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 6, 2026 | 8-K | Amended articles or bylaws | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| Jul 29, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 29, 2026 | 8-K | Shareholder vote | Document |
| Jun 10, 2026 | DEFA14A | Additional annual meeting material | Document |
| May 13, 2026 | 8-K | Other material events | Document |
| May 13, 2026 | S-8 | Shares registered for employees | Document |
| May 13, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 13, 2026 | 8-K | Results of operations | Document |
| Apr 28, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 27, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Mar 10, 2026 | 8-K | Regulation FD disclosure | Document |
| Mar 10, 2026 | 8-K | Results of operations | Document |
| Mar 10, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 26, 2026 | 8-K | Regulation FD disclosure | Document |
| Feb 2, 2026 | 8-K | Material agreement entered | Document |
| Dec 19, 2025 | 8-K | Amended articles or bylaws | Document |
| Dec 9, 2025 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Nov 24, 2025 | EFFECT | Filing | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since May 14, 2015.
The full analysis
What do vTv Therapeutics's filings show?
The filings are where every one of vTv Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.